Abstracts tagged "Antiphospholipid antibodies"

Abstract Number: 2868 • 2014 ACR/ARHP Annual Meeting
Antiphospholipid Syndrome Alliance for Clinical Trials and International Networking (APS ACTION) Clinical Database and Repository Initial Analysis
Doruk Erkan¹, Danieli Andrade², Maria Tektonidou³, Amaia Ugarte⁴, Alessandra Banzato⁵, Angela Tincani⁶, Pier-Luigi Meroni⁷, Ricard Cervera⁸, Paul R. Fortin⁹, Roger A. Levy¹⁰ and On Behalf of APS Action¹¹, ¹Rheumatology, Hospital for Special Surgery, New York, NY, ²Rheumatology, University of São Paulo, São Paulo, Brazil, ³First Department of Internal Medicine, Laikon Hospital, Athens University Medical School, Athens, Greece, ⁴Hospital Universitario Cruces, Bizkaia, Spain, ⁵Department of Cardiac Thoracic and Vascular Sciences, Department of Cardiac Thoracic and Vascular Sciences, University of Padua, Padua, Italy, ⁶Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ⁷Int Medicine, University of Milan, Milano, Italy, ⁸Hospital Clinic, Barcelona, Spain, ⁹Rheumatology, Laval University, Division of Rheumatology, Centre de Recherche du CHU de Québec and Department of Medicine, Quebec City, QC, Canada, ¹⁰Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ¹¹APS ACTION, New York, NY
Background/Purpose: APS ACTION International Clinical Database and Repository (“Registry”) was created to study the natural course of disease over 10 years in persistently aPL-positive patients…
Abstract Number: 2650 • 2014 ACR/ARHP Annual Meeting
Cognitive Impairment in SLE and Non-Criterion Anti-Phospholipid Antibodies
Michael Luggen¹, Gaurav Gulati², Rohan Willis³ and Emilio B. Gonzalez³, ¹Division of Immunology, Allergy, and Rheumatology, University of Cincinnati College of Medicine, Cincinnati, OH, ²Division of Immunology, Allergy & Rheumatology, University of Cincinnati College of Medicine, Cincinnati, OH, ³Rheumatolgoy/Dept Int Med, University of Texas Medical Branch, Galveston, TX
Background/Purpose: The pathogenesis of cognitive impairment (CI) in patients with SLE is unknown. Anti-phospholipid antibodies (APL) have been implicated in some studies, but not in…
Abstract Number: 2638 • 2014 ACR/ARHP Annual Meeting
The Protective Effects of Statins for Thrombosis in Patients with Systemic Lupus Erythematosus Positive for Antiphospholipid Antibodies
Toshiyuki Watanabe, Kenji Oku, Olga Amengual, Eri Sugawara, Ryo Hisada, Kazumasa Ohmura, Tomoko Fukui, Sanae Shimamura, Ikuma Nakagawa, Atsushi Noguchi, Haruki Shida, Michihito Kono, Yuka Shimizu, Takashi Kurita, Toshiyuki Bohgaki, Tetsuya Horita, Shinsuke Yasuda and Tatsuya Atsumi, Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan
Background/Purpose: Thrombosis is one of the most frequent manifestations in patients with systemic lupus erythematosus (SLE). Although antiphospholipid antibodies (aPL) are well recognized risk factors…
Abstract Number: 1702 • 2014 ACR/ARHP Annual Meeting
Antiphospholipid Antibodies in Systemic Sclerosis: Prevalence and Clinical Significance?
Anjali Shetty¹, Suncica Volkov¹, Claudia Vergara² and William Swedler³, ¹Medicine/Rheumatology, University of Illinois at Chicago, Chicago, IL, ²Rheumatology, University of Illinois Chicago, Chicago, IL, ³Section of Rheumatology, University of Illinois at Chicago, Chicago, IL
Background/Purpose: Systemic Sclerosis (SSc) is an autoimmune disease characterized by collagen deposition and vascular changes of the skin and internal organs, leading ultimately to fibrosis. …
Abstract Number: 1664 • 2014 ACR/ARHP Annual Meeting
Novel Risk Factors for Systemic Lupus Erythematosus (SLE) Flares in Patients with End-Stage Renal Disease: Is SLE in Patients with End-Stage Renal Disease a “sleeping beauty”?
Jorge Alcocer-Varela¹, Mariana Quintanar², Javier Merayo-Chalico³, Ana Barrera-Vargas¹ and Diana Gómez-Martín¹, ¹Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ²Internal Medicine, Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", Mexico City, Mexico, ³Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose Renal involvement in systemic lupus erythematosus (SLE) is frequent, and a high percentage of patients (~15%) develop end-stage renal disease (ESRD) even with optimal…
Abstract Number: 1342 • 2014 ACR/ARHP Annual Meeting
Improving Serologic Testing for Antiphospholipid Antibodies in Patients with Systemic Lupus Erythematosus
Arshad Mustafa¹, Kara Prescott², Una Makris³ and E. Blair Solow⁴, ¹Internal Medicine - Rheumatology, UT Southwestern Medical Center at Dallas, Dallas, TX, ²Internal Med - Rheumatology, Dallas VA Medical Ctr, Dallas, TX, ³Rheumatology, Dallas VA Medical Ctr, Dallas, TX, ⁴Internal Medicine, Division of Rheumatic Diseases, UT Southwestern Medical Center, Dallas, TX
Background/Purpose: Antiphospholipid antibodies (APL) in patients with Systemic Lupus Erythematosus (SLE) are common. Persistent positivity is known to increase the risk of thrombosis and pregnancy…
Abstract Number: 3 • 2013 ACR/ARHP Annual Meeting
The Global Antiphospholipid Syndrome Score (GAPSS) In Primary APS
Savino Sciascia¹, Giovanni Sanna², Veronica Murru³, Dario Roccatello¹, Munther A. Khamashta⁴ and Maria Laura Bertolaccini³, ¹Department of Rare, Immunologic, Hematologic and Immunohematologic Diseases, Centro di Immunopatologia e Documentazione su Malattie rare, Torino, Italy, ²Louise Coote Lupus Unit, St. Thomas' Hospital, London, United Kingdom, ³Lupus Research Unit, The Rayne Institute, Kings College London School of Medicine, London, United Kingdom, ⁴Lupus Research Unit, The Rayne Institute, St Thomas Hospital, Kings College London School of Medicine, London, United Kingdom
Background/Purpose: Antiphospholipid Syndrome (APS) is a heterogeneous entity with a wide variation in clinical course and laboratory profile. We aimed to evaluate the clinical utility…
Abstract Number: 4 • 2013 ACR/ARHP Annual Meeting
Proteomic Analyses Of Monocyte Responses To IgG From Patients With Antiphospholipid Syndrome
Vera M. Ripoll¹, Anastasia Lambrianides², Wendy Heywood³, Anisur Rahman⁴, Yiannis Ioannou⁵ and Ian Giles⁶, ¹Centre for Rheumatology, Rayne Institute, 4th floor, Centre for Rheumatology, University College London, London, United Kingdom, ²Centre for Rheumatology Research, University College London, London, United Kingdom, ³Institute of Child Health, University College London, London, United Kingdom, ⁴Centre for Rheumatology Research,Rayne Institute, 4th Floor, University College London, London, United Kingdom, ⁵Arthritis Research UK Centre for Adolescent Rheumatology, University College London, London, United Kingdom, ⁶Centre for Rheumatology, Division of Medicine, Centre for Rheumatology, University College London, London, United Kingdom
Background/Purpose: Antiphospholipid syndrome (APS) is an autoimmune disorder characterised by recurrent vascular thrombosis (VT) and/or pregnancy morbidity (PM) caused by antiphospholipid antibodies (aPL). Whilst aPL are known…
Abstract Number: 8 • 2013 ACR/ARHP Annual Meeting
Clinical Evaluation Of Two Anti-Beta₂glycoprotein I Domain 1 Autoantibody Assays To Aid In The Diagnosis and Risk Assessment Of The Antiphospholipid Syndrome
Rohan Willis¹, Michael Mahler², Francesca Pregnolato³, Charis Pericleous⁴, Anisur Rahman⁵, John Ioannou⁶, Ian Giles⁵, Gabriella Lakos², Roger Albesa², Navid Zohoury², Pier-Luigi Meroni⁷ and Silvia S. Pierangeli⁸, ¹Int Medicine/Rheumatology, University of Texas Medical Branch, Galveston, TX, ²Research, INOVA Diagnostics, San Diego, CA, ³Lab of Immunology, IRCCS Istituto Auxologico Italiano, Milan, Italy, ⁴Centre for Rheumatology, Division of Medicine, Centre for Rheumatology, University College London, London, United Kingdom, ⁵Centre for Rheumatology Research,Rayne Institute, 4th Floor, University College London, London, United Kingdom, ⁶Rayne Institute, University College London, London, UK, London, United Kingdom, ⁷Int Medicine, University of Milan, Milano, Italy, ⁸Rheumatology/Dept Int Med, University of Texas Medical Branch, Galveston, TX
Background/Purpose: Antiphospholipid Syndrome (APS) is characterized by the presence of antibodies to phospholipids (aPL) and to β2glycoprotein I (β2GPI) in patients with thrombosis or pregnancy…
Abstract Number: 9 • 2013 ACR/ARHP Annual Meeting
Domain 1 Is The Main Specificity Of Anti-β₂glycoprotein I Antibodies In Systemic Autoimmune Diseases
Laura Andreoli¹, Cecilia Nalli¹, Maria-Orietta Borghi², Francesca Pregnolato³, Alessandra Zanola⁴, Claudia Grossi⁵, Maria Gerosa⁶, Flavio Allegri⁴, Michael Mahler⁷, Gary L. Norman⁷, Pier Luigi Meroni⁸ and Angela Tincani¹, ¹Rheumatology Unit, University of Brescia, Brescia, Italy, ²Lab of immunology, IRCCS Istituto Auxologico Italiano, Department of Clinical Sciences and Community Health, University of Milan, Milano, Italy, ³Lab of Immunology, IRCCS Istituto Auxologico Italiano, Milan, Italy, ⁴Rheumatology and Clinical Immunology, Spedali Civili and University of Brescia, Brescia, Italy, ⁵Laboratory of Immuno-rheumatology, IRCCS Istituto Auxologico Italiano, Milan, Italy, ⁶Division of Rheumatology, Gaetano Pini Institute, Department of Clinical Sciences and Community Health, University of Milan, Milan, Italy, ⁷Research, INOVA Diagnostics, San Diego, CA, ⁸Division of Rheumatology, Gaetano Pini Institute, Milano, Italy
Background/Purpose: Anti-β2glycoprotein I antibodies (a-β2GPI) are involved in the pathogenesis of the Antiphospholipid Syndrome (APS). Antibodies to the domain 1 of β2GP1 (a-β2GPI-D1) have been…
Abstract Number: 10 • 2013 ACR/ARHP Annual Meeting
Autoantibodies Targeting Domain 1 Of Beta 2 Glycoprotein I As Promising Marker In The Diagnosis and Risk Stratification Of The Antiphospholipid Syndrome
Navid Zohoury¹, Munther A. Khamashta², Tatsuya Atsumi³, Jacek Musial⁴, Toshiyuki Watanabe⁵, Maria Papp⁶, Concepción González-Rodríguez⁷, Roger Albesa¹, Gary L. Norman¹, Pier-Luigi Meroni⁸ and Michael Mahler¹, ¹Research, INOVA Diagnostics, San Diego, CA, ²Lupus Research Unit, The Rayne Institute, St Thomas Hospital, Kings College London School of Medicine, London, United Kingdom, ³Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Sapporo, Japan, ⁴Depment of Medicine, Jagiellonian University Medical College, Krakow, Poland, ⁵Division of Rheumatology, Endocrinology and Nephrology, Hokkaido University Graduate School of Medicine, Hokkaido, Japan, ⁶MHSCInstitute of Medicine, Department of Gastroenterology, University of Debrecen, Debrecen, Hungary, ⁷University Hospital Virgen Macarena, Sevilla, Spain, ⁸Int Medicine, University of Milan, Milano, Italy
Background/Purpose: Antiphospholipid Syndrome (APS) is characterized by the presence of antibodies to phospholipids (aPL) and to β2glycoprotein I (β2GPI) in patients with thrombosis or pregnancy…
Abstract Number: 14 • 2013 ACR/ARHP Annual Meeting
Isotype Dependent Performance Of Beta₂glycoprotein I Immunoassays In Two Diverse Patient Cohorts: Implications For Assay Harmonization and Standardization
Anne E. Tebo^1,2, Rohan Willis³, Troy Jaskowski⁴, Jane E. Salmon⁵, Michelle Petri⁶, Ware D. Branch^7,8 and Silvia S. Pierangeli³, ¹Pathology, University of Utah, Salt Lake City, UT, ²Medical Directorship, ARUP Laboratories, Salt Lake City, UT, ³Rheumatology/Dept Int Med, University of Texas Medical Branch, Galveston, TX, ⁴ARUP Laboratories, Salt Lake City, UT, ⁵Rheumatology, Hospital for Special Surgery, New York, NY, ⁶Johns Hopkins University School of Medicine, Baltimore, MD, ⁷Obsterics and Gynecology, Univ of Utah, Salt Lake City, UT, ⁸Intermountain Healthcare, Salt Lake City, UT
Background/Purpose: The presence IgG and/or IgM beta2 glycoprotein I (β2GPI) antibodies are associated with thrombosis and/or pregnancy-related morbidity in antiphospholipid syndrome (APS) and/or systemic lupus…
Abstract Number: 18 • 2013 ACR/ARHP Annual Meeting
Clinical Correlates Of Positive Anti-Cardiolipin and β-2 Glycoprotein 1 Antibodies In a Cohort Of 110 Patients At Mayo Clinic
Uma Thanarajasingam¹, Cynthia S. Crowson², Melissa R. Snyder³, Rajeev Pruthi⁴, Harvinder S. Luthra⁵ and Kevin G. Moder⁶, ¹Division of Rheumatology, Mayo Clinic, Rochester, MN, ²Department of Health Sciences Research, Mayo Clinic, Rochester, MN, ³2Division of Clinical Biochemistry and Immunology, Department of Laboratory Medicine and Pathology, Mayo Clinic, Rochester, MN, ⁴Divison of Hematology, Mayo Clinic, Rochester, MN, ⁵Medicine/Division of Rheum, Mayo Clinic, Rochester, MN, ⁶Rheumatology, Mayo Clinic, Rochester, MN
Background/Purpose: Testing for antiphospholipid antibodies is typically indicated for diagnosis and prognosis of antiphospholipid syndromes, however, selected patients undergo testing for other reasons. The clinical…
Abstract Number: 2651 • 2013 ACR/ARHP Annual Meeting
The Association Between Antiphospolipid Antibodies and Related Clinical Outcomes: A Critical Review Of The Literature
Cecilia B. Chighizola¹, Laura Andreoli², Alessandra Banzato³, Guilherme Ramires de Jesus⁴, Guillermo J. Pons-Estel⁵, Doruk Erkan⁶ and On Behalf of APS Action⁷, ¹Rheumatology, Istituto Auxologico Italiano, University of Milan, Cusano Milanino, Italy, ²Rheumatology Unit, University of Brescia, Brescia, Italy, ³Department of Cardiac Thoracic and Vascular Sciences, Department of Cardiac Thoracic and Vascular Sciences, University of Padua, Padua, Italy, ⁴Department of Obstetrics, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil, ⁵Servicio de Enfermedades Autoinmunes, Department of Autoimmune Diseases, Institut Clìnic de Medicina i Dermatologia, Hospital Clìnic, Barcelona, Spain, ⁶Rheumatology, Hospital for Special Surgery, New York, NY, ⁷APS ACTION, New York, NY
Background/Purpose: AntiPhospholipid Syndrome Alliance For Clinical Trials and InternatiOnal Networking (APS ACTION) is an international network that has been created to design and conduct APS…
Abstract Number: 2654 • 2013 ACR/ARHP Annual Meeting
IgG Antibodies Directed Against Domain I Of ß₂-Glycoprotein I Are Significant Predictors Of Thromboembolic Events In Patients With Antiphospholipid Antibodies. A Prospective Cohort Study
Stephane Zuily¹, Bas de Laat², Francis Guillemin³, Pierre Kaminsky⁴, Hilde Kelchtermans⁵, Roger Albesa⁶, Gary L. Norman⁶, Anne-Christine Rat⁷, Philip de Groot⁸, Thomas Lecompte⁹, Veronique Regnault¹⁰ and Denis Wahl¹, ¹CHU de Nancy, Vascular Medicine Division and Regional Competence Center For Rare Vascular And Systemic Autoimmune Diseases, Nancy, F-54000, France; Inserm, UMR_S 1116, Nancy, F-54000, France; Université de Lorraine, Nancy, F-54000, France, Nancy, France, ²Biochemistry, CARIM, Maastricht University, The Netherlands; Clinical Chemistry and Hematology, UMC Utrecht, The Netherlands; Synapse BV, Maastricht, The Netherlands; Sanquin Research, Amsterdam, The Netherlands, Maastricht, Netherlands, ³CHU Nancy, Clinical Epidemiology and Evaluation, Université de Lorraine, Paris Descartes University, APEMAC, EA 4360, Nancy, France, ⁴Université de Lorraine, Nancy, F-54000, France; CHU de Nancy, Orphan disease unit, Nancy, F-54000, France;, Nancy, France, ⁵Biochemistry, CARIM, Maastricht University, The Netherlands; Synapse BV, Maastricht, The Netherlands, Maastricht, Netherlands, ⁶Research, INOVA Diagnostics, San Diego, CA, ⁷Université de Lorraine, Nancy, F-54000, France; Inserm, CIC-EC CIE6, Nancy, F-54000, France; CHU de Nancy, Clinical Epidemiology and Evaluation Department, Nancy, F-54000, France; CHU de Nancy, Rheumatology department, Nancy, France, ⁸Clinical Chemistry and Hematology, UMC Utrecht, The Netherlands, Utrecht, Netherlands, ⁹Inserm, UMR_S 1116, Nancy, F-54000, France; Université de Lorraine, Nancy, F-54000, France; CHU de Nancy, Haematology Laboratory, Nancy, F-54000, France; Division of Haematology, HUG, Geneva, Switzerland (current address), Geneva, Switzerland, ¹⁰Inserm, UMR_S 1116, Nancy, F-54000, France; Université de Lorraine, Nancy, F-54000, France; CHU de Nancy, Contrat d’interface, Nancy, F-54000, France, Nancy, France
AbstractBackground/Purpose : Our objective was to prospectively determine the prognostic significance of laboratory variables regarding thrombotic events during follow-up, including novel assays IgG antibodies directed…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].